Mylan gets DCGI Approval to launch its Generic Version of Remdesivir ‘DESREM’ at Rs 4800
Global pharmaceutical company Mylan N.V was given approval by the Drug Controller General of India (DCGI) for the launch of its generic version of Gilead Sciences Remdesivir drug for the treatment of COVID-19 positive patients in India. Mylan N.V is currently the second-largest company in the world for the manufacturing of generic and specialty pharmaceuticals.
Mylan N.V’s DESREM is the third generic version of Remdesivir to get DCGI approval for sale in India. In the month of June 2020, generic versions of Indian pharmaceutical companies – Cipla’s CIPREMI and Hetero’s COVIFOR’ has got DCGI approval.
Brandname for Marketing
Under the brand name ‘DESREM’, Mylan N.V’s generic version of Remdesivir will be marketed in India.
Price and Availability
As it is an injectable drug, it has to be administered under the supervision of a healthcare practitioner and will not be available through any retail channel. The drug will be made available for hospitals and government healthcare agencies.
It will be available in a 100mg injectable dose. The price will be in the range of Rs 4,800. DESREM will be available by the last week of July 2020 in India.
In May 2020, clinical trials conducted under ACTT-1 (Adaptive COVID-19 Treatment Trial) with Remdesivir in more than 60 centers across the United States, Asia, and Europe had shown promising results when compared with the patients who were given placebo. During the trails a total of 1063 patients were given Remdesivir, the mortality rate was 7.1 %.
Japan was the first country to approve Remdesivir drug as a treatment for COVID-19. At present Remdesivir is only available in the injectable method. On 22nd June 2020, Gilead Sciences had announced had it will soon start Phase I trial for the inhaled version of Remdesivir.
United Kingdom, Singapore, and Japan are the countries where the drug has been approved to date for the treatment of COVID-19 cases.
The antiviral drug ‘Remdesivir’ is administered via injection into a vein. This antiviral medication was developed by the United States biopharmaceutical company Gilead Sciences for treatment of Hepatitis C.
Categories: Science & Tech Current Affairs